Dassault Systèmes moved to consolidate life-science data and analytics capabilities by agreeing to acquire Arisglobal for up to $2 billion. The deal is designed to merge Arisglobal’s AI-driven safety and regulatory intelligence tools with Dassault’s scientific modeling and simulation assets. The combined platform is intended to unify “real-world evidence” and “virtual evidence,” addressing a persistent industry problem: fragmented datasets across clinical, safety, regulatory, and modeling workflows. For sponsors and CRO partners, this could shift how submissions and evidence packages are assembled as AI-enabled workflows become embedded in regulatory operations. The acquisition also signals continued corporate investment in regulated AI tooling for life sciences, as large platforms try to become the backbone for both analytics and operational decision support.